ATE458493T1 - Immunogene lhrh zusammensetzungen sowie damit zusammenhängende verfahren - Google Patents

Immunogene lhrh zusammensetzungen sowie damit zusammenhängende verfahren

Info

Publication number
ATE458493T1
ATE458493T1 AT98931835T AT98931835T ATE458493T1 AT E458493 T1 ATE458493 T1 AT E458493T1 AT 98931835 T AT98931835 T AT 98931835T AT 98931835 T AT98931835 T AT 98931835T AT E458493 T1 ATE458493 T1 AT E458493T1
Authority
AT
Austria
Prior art keywords
related methods
immunogenic lhrh
lhrh compositions
immunogenic
compositions
Prior art date
Application number
AT98931835T
Other languages
English (en)
Inventor
Michael Mcnamara
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE458493T1 publication Critical patent/ATE458493T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT98931835T 1997-07-09 1998-07-09 Immunogene lhrh zusammensetzungen sowie damit zusammenhängende verfahren ATE458493T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7768A AUPO776897A0 (en) 1997-07-09 1997-07-09 A method of achieving production gains in livestock and agents useful for same
PCT/AU1998/000532 WO1999002180A1 (en) 1997-07-09 1998-07-09 Immunogenic lhrh compositions and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE458493T1 true ATE458493T1 (de) 2010-03-15

Family

ID=3802056

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931835T ATE458493T1 (de) 1997-07-09 1998-07-09 Immunogene lhrh zusammensetzungen sowie damit zusammenhängende verfahren

Country Status (19)

Country Link
US (6) US7534441B2 (de)
EP (4) EP1007084B1 (de)
JP (3) JP5116916B2 (de)
KR (2) KR20060101554A (de)
AT (1) ATE458493T1 (de)
AU (2) AUPO776897A0 (de)
CA (1) CA2294865C (de)
CY (2) CY1109968T1 (de)
DE (2) DE122010000033I1 (de)
DK (1) DK1007084T3 (de)
ES (1) ES2339308T3 (de)
FR (2) FR10C0035I2 (de)
LU (1) LU91711I2 (de)
NZ (1) NZ502080A (de)
PL (1) PL200495B1 (de)
PT (1) PT1007084E (de)
TW (1) TWI235666B (de)
WO (1) WO1999002180A1 (de)
ZA (1) ZA986074B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ATE286511T1 (de) 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20090028886A1 (en) * 2004-08-04 2009-01-29 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
EP1890725A2 (de) * 2005-06-01 2008-02-27 Pfizer Products Inc. Impfstoffzusammensetzungen und verfahren zur behandlung von harninkontinenz
WO2008110912A1 (en) * 2007-03-14 2008-09-18 Pfizer Inc. Fertility regulation in horses
MY176727A (en) 2012-12-03 2020-08-20 Pfizer Selective androgen receptor modulators
KR101918381B1 (ko) * 2017-01-11 2018-11-13 이경민 칠보 공예품을 제조하는 방법과 이에 의하여 제조되는 칠보 공예품
KR102477054B1 (ko) * 2020-03-24 2022-12-14 주식회사 바이오앱 웅취 제거용 재조합 단백질 및 이를 포함하는 백신 조성물
AU2024296166A1 (en) * 2023-07-07 2025-09-25 Ouro Fino Saúde Animal Ltda Modified gnrh peptide and its conjugate for mammalian immunocastration, manufacturing method, composition and kit

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
NZ220932A (en) * 1986-07-03 1990-05-28 Victoria State Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
WO1988005308A1 (en) * 1987-01-14 1988-07-28 Commonwealth Scientific And Industrial Research Or Anti reproductive hormone
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
WO1990009799A1 (en) * 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
NL8900726A (nl) 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
ATE140972T1 (de) 1989-08-25 1996-08-15 Biotech Australia Pty Ltd Fusionsproteine bestehend aus tratp und mindestens einem lhrh-analog
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
ES2149166T3 (es) * 1991-03-01 2000-11-01 Merial Sas Procedimiento de inmunoneutralizacion anti-lhrm de los animales domesticos machos no castrados y peptido para su realizacion.
EP0596959B1 (de) * 1991-07-26 2000-03-29 Commonwealth Scientific And Industrial Research Organisation System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5885966A (en) * 1995-06-07 1999-03-23 Dlo Instituut Voor Dierhouderij En Diergezondheid Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
WO1996040755A1 (en) 1995-06-07 1996-12-19 Dlo Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) An improved peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone lhrh, and analogs of the lhrh tandem repeat peptide and their use as vaccine
WO1997015316A1 (en) 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines

Also Published As

Publication number Publication date
DE69841521D1 (de) 2010-04-08
KR20010021623A (ko) 2001-03-15
US20060024290A1 (en) 2006-02-02
US20090226484A1 (en) 2009-09-10
ZA986074B (en) 1999-03-16
EP2196213A1 (de) 2010-06-16
JP2010059167A (ja) 2010-03-18
FR10C0035I2 (fr) 2012-06-22
CY2010013I1 (el) 2012-01-25
EP1007084A4 (de) 2003-07-02
WO1999002180A1 (en) 1999-01-21
CY1109968T1 (el) 2012-01-25
AU8200198A (en) 1999-02-08
ES2339308T3 (es) 2010-05-18
DE122010000033I1 (de) 2011-12-01
TWI235666B (en) 2005-07-11
JP2013006862A (ja) 2013-01-10
NZ502080A (en) 2001-09-28
EP1007084B1 (de) 2010-02-24
JP5231378B2 (ja) 2013-07-10
AU725562B2 (en) 2000-10-12
JP5116916B2 (ja) 2013-01-09
US20120328639A1 (en) 2012-12-27
FR10C0035I1 (fr) 2010-08-27
PL338037A1 (en) 2000-09-25
CY2010013I2 (el) 2012-01-25
US7534441B2 (en) 2009-05-19
US8741303B2 (en) 2014-06-03
AUPO776897A0 (en) 1997-07-31
PL200495B1 (pl) 2009-01-30
EP1007084A1 (de) 2000-06-14
EP2191839A3 (de) 2010-09-08
PT1007084E (pt) 2010-04-08
EP2191839A2 (de) 2010-06-02
US20090291098A1 (en) 2009-11-26
CA2294865C (en) 2013-05-21
EP2316477A1 (de) 2011-05-04
KR20060101554A (ko) 2006-09-25
DK1007084T3 (da) 2010-05-03
KR100680631B1 (ko) 2007-02-09
FR10C0040I1 (fr) 2010-10-15
US20140271695A1 (en) 2014-09-18
JP2001509489A (ja) 2001-07-24
CA2294865A1 (en) 1999-01-21
LU91711I2 (fr) 2010-09-28
US20110293647A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
FR10C0035I2 (fr) Composition immunogene de lh-rh et procedes concernant cette composition
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2001053463A3 (en) COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
WO1999054326A8 (de) Dihydropyrimidine
IL159724A0 (en) A nitrogen oxide generating composition for treatment of nail infections
EP1378240A3 (de) Pharmazeutische Zusammensetzungen enthaltend Arsen zur Behandlung von multiplen Myelom
MY139523A (en) Ziprasidone composition and synthetic controls
DE60236814D1 (de) 3-alkyl-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthole und 3,3'-dialkyl-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthole, sowie verfahren zur ihrer herstellung
SG2010079697A (en) Aminocyclohexyl ether compounds and uses thereof
WO2002066672A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
WO2001040177A3 (en) Esters of vitamin d3 and uses thereof
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2002096420A3 (en) Method for treating nerve injury caused by surgery
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
AP2001002248A0 (en) Method for treating COPD.
WO2006029823A3 (de) Verfahren zum behandeln von metallischen oberflächen unter verwendung von formulierungen auf basis von wasserarmer methansulfonsäure
MXPA02012112A (es) Composiciones que contienen policarbonato.
CA2534483A1 (en) Composition and method for treating bezoar and trichobezoar
WO2002066666A3 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
WO2002066665A3 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
BG103087A (en) Method for the preparation of naphthiridons and intermediate compounds
AU2001273872A1 (en) A method for treatment of resin-containing wood
GR1003358B (el) Διαδικασια παραγωγης 1,2-διμεθυλ-3-υδροξυπυριδ-4-ονης